OptiNose

OptiNose develops nasal drug delivery technologies and novel combination drug/device therapies. The drug delivery technologies are based upon a unique and patent-protected principal Bi-Directional Delivery which allows drugs to be more efficiently delivered to the nasal cavity. By applying the Company's drug delivery technology, most of the dose is deposited beyond the nasal valve in the upper posterior two-thirds of the nasal cavity, unlike traditional devices.

The OptiNose delivery devices have high dose reproducibility and avoid drug deposition to the lungs. In summary, the technology fulfills the ideal requirements for nasal drug delivery. Clinical trials have shown the devices can provide a faster onset of action, greater effect with a lower dose and reduced side effects.

Company Growth (employees)
Type
Private
HQ
Oslo, NO
Founded
2000
Size (employees)
40 (est)+3%
OptiNose was founded in 2000 and is headquartered in Oslo, NO

Key People at OptiNose

Peter K. Miller

Peter K. Miller

CEO
Ramy A. Mahmoud

Ramy A. Mahmoud

COO
Per G. Djupesland

Per G. Djupesland

CSO

OptiNose Office Locations

OptiNose has offices in Oslo and Berkeley
Oslo, NO (HQ)
Oslo Innovation Center
Berkeley, US
Berkeley House

OptiNose Data and Metrics

Summary Metrics

Founding Date

2000

Total Funding

$120.5 m

Latest funding size

$37 m

Time since last funding

5 months

Investors

OptiNose's latest funding round in May 2017 was reported to be $37 m. In total, OptiNose has raised $120.5 m

Traffic Overview of OptiNose

OptiNose News and Updates

This Biotech Wants to Make Taking Your Medicine as Easy as Breathing

OptiNose's flagship device is a unique drug delivery system.

OptiNose Company Life and Culture

You may also be interested in